<DOC>
	<DOC>NCT02332798</DOC>
	<brief_summary>This study aims to assess the safety, tolerability and pharmacokinetics of PF-04958242 in multiple ascending doses in subjects with stable schizophrenia.</brief_summary>
	<brief_title>Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia</brief_title>
	<detailed_description>This study aims to assess the safety, tolerability and pharmacokinetics of PF-04958242 compared to placebo over 14 days twice a day dosing in multiple ascending doses in subjects with stable schizophrenia.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Psychiatrically stable (≥3 months) male and female subjects with schizophrenia of nonchildbearing potential between the ages of 18 and 55 years, inclusive. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;55 kg (121 lbs). DSMIV Diagnosis of Schizophrenia; on stable medication treatment regimen ≥2 months. Suicide attempt within 3 months prior to screening. History of or risk of seizures; head injury with long term abnormal resulting condition, abnormal EEG, clinically significant additional diseases or conditions, current medication with a significant risk of seizures, currently receiving antipsychotic medications.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Multiple ascending doses</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>cognitive impairment associated with schizophrenia (CIAS)</keyword>
</DOC>